On the heels of new FDA and European Commission approvals for ALIMTA((R)) (pemetrexed for injection) as a treatment for nonsquamous non-small cell lung cancer (NSCLC) in the maintenance setting, the company will release findings from more than 30 lung cancer studies at the 13th World Conference on Lung Cancer (WCLC) in San Francisco, Calif., from July 31 to Aug. 4, 2009. WCLC is sponsored by the International Association for the Study of Lung Cancer. Data will feature Lilly's ALIMTA and GEMZAR((R)) (gemcitabine HCl for injection).
"Our goal is - and has always been - to improve treatment options for individual patients," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "In lung cancer in particular, histology provides us with one way to tailor treatment with ALIMTA for patients living with nonsquamous NSCLC."
ALIMTA, launched in 2004, continues to be evaluated in a number of NSCLC treatment settings. At WCLC, the company will share data involving ALIMTA-based regimens in combination with radiation for inoperable stage IIIA/B NSCLC.
Globally, lung cancer impacts more than 3 million people and is one of the most common cancers worldwide, accounting for 1.2 million new cases annually.(i)
Studies of note for ALIMTA include:
-- B2.6: Oral Presentation: Aug. 2, 2009, 3:30 p.m. PDT
-- Pemetrexed is more effective* in patients with nonsquamous non-small
cell lung cancer (NSCLC) histology: An analysis of three large,
randomized, phase III trials (* vs. the respective comparators in
these three trials)
-- D2.6: Oral Presentation: Aug. 4, 2009, 1:30 p.m. PDT
-- Final results of a randomized phase II trial of pemetrexed (P) +
carboplatin (Cb) +/- enzastaurin (E) versus docetaxel (D) + Cb as
first-line treatment of patients (pts) with stage IIIB/IV non-small
cell lung cancer (NSCLC)
-- PD9.1.1: Poster Discussion Session: Aug. 3, 2009, 10:30 a.m. PDT
-- Histological analysis in Pemetrexed treated patients with stage
IIIB/IV NSCLC: Results from an open label randomized phase II study
-- PD8.1.3: Poster Discussion Session: Aug. 3, 2009, 10:30 a.m. PDT
-- Ongoing Phase II Study of Pemetrexed plus Carboplatin or Cisplatin
with Concurrent Radiation Therapy Followed by Pemetrexed
Consolidation in Patients with Favorable-Prognosis Inoperable Stage
IIIA/B non-small cell Lung Cancer: Interim Safety Update
Want to read more?
MabThera receives positive opinion in Europe
Ilaris® recommended for European approval
FDA Approves Expanded Use of Lilly's FORTEO(R)
